Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

Completed · Phase 2 · Has a placebo group

Conditions studied: Systolic Heart Failure

In brief

Probenecid is an FDA approved drug for the treatment gout and hyperuricemia. It has been used safely in humans for decades for this and other indications. The investigators have recently discovered that this drug can also stimulate other receptors in the heart and therefore improve its function. The hypothesis of this study is that probenecid can be used to improve the function of the heart and therefore the symptoms in patients with heart failure.

Key facts

Study ID

NCT01814319

Run by

University of Cincinnati

People needed

20

Starts

2013-03-01

Expected to finish

2015-06-01

Last updated by the study team

2015-08-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• EF < 40% via echocardiogram within the past 12 months
• Stable dose of heart failure medications for > past 1 month
• NYHA class II - IV

You may not qualify if…

• Pregnant or lactating female
• Receiving IV inotrope
• History of significant non-compliance
• Unwilling to adhere to the protocol
• Systemic systolic BP less than 90 mmHg at screening visit
• History of allergy to probenecid
• History of gout
• History of renal calculi
• Recent unstable coronary artery syndromes (USA, admission to hospital for AMI, revascularization procedure, or acute decompensated HF requiring hospitalization) within the past 3 months.
• Implant of CRT device within the past 3 months
• TIA, CVA or major surgery within the past 3 months
• Valvular heart disease (more than moderate stenosis or insufficiency)
• HOCM, myocarditis, constrictive pericarditis, congenital heart disease, 14 Active chemotherapy, significant malignancy or uncontrolled metabolic disease (untreated hyper or hypothyroidism, Cushing's disease etc.)What about uncontrolled DM?? HgA1C > etc
• Elevated liver enzymes (> 3 times ULN), 16. Current atrial fibrillation or frequent PVCs (should we define this now) 17. End stage renal disease (dialysis dependent) or worsening renal insufficiency should define now.
• History of gastric ulcerations, significant gastroesophageal reflux. 19. Other condition that in the opinion of the investigator, would make the subject a poor candidate for the study.
• Co-administration of any medication that in the opinion of the investigator places the subject at increased risks due to potential adverse drug interactions.

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.